2023
DOI: 10.1021/acs.molpharmaceut.2c00957
|View full text |Cite
|
Sign up to set email alerts
|

Gallium-68-Labeled ZPDGFRβ Affibody: A Potential PET Probe for Platelet-Derived Growth Factor Receptor β-Expressing Carcinomas

Abstract: Platelet-derived growth factor receptor β (PDGFRβ) has been demonstrated to be an effective biomarker for a variety of malignant cancers, and affibody-based PDGFRβ molecules have potential as positron emission tomography (PET) tracers for the diagnosis of cancers. Based on previous pharmacokinetics studies, short-lived positron emission radionuclides, such as fluorine-18 and gallium-68, would be more suitable for affibody-based PET imaging. Thus, in the present study, we prepared a gallium-68-labeled PDGFRβ-ta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…Radioligand [ 18 F]2 was selected for the cell binding study because of its favorable partition coefficient compared to that of [ 18 F]1 and was evaluated in vitro with and without FAPI-04 using U87MG cells expressing FAP. 38 The results confirmed that the cell binding of [ 18 F]2 was FAP-specific (Figure 2B).…”
Section: ■ Discussionmentioning
confidence: 99%
“…Radioligand [ 18 F]2 was selected for the cell binding study because of its favorable partition coefficient compared to that of [ 18 F]1 and was evaluated in vitro with and without FAPI-04 using U87MG cells expressing FAP. 38 The results confirmed that the cell binding of [ 18 F]2 was FAP-specific (Figure 2B).…”
Section: ■ Discussionmentioning
confidence: 99%